The economic case for precision medicine

Sean P. Gavan, Alexander J. Thompson and Katherine Payne

Manchester Centre for Health Economics, Division of Population Health, Health Services Research and Primary Care, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

ABSTRACT
Introduction: The advancement of precision medicine into routine clinical practice has been highlighted as an agenda for national and international health care policy. A principle barrier to this advancement is in meeting requirements of the payer or reimbursement agency for health care. This special report aims to explain the economic case for precision medicine, by accounting for the explicit objectives defined by decision-makers responsible for the allocation of limited health care resources.

Areas covered: The framework of cost-effectiveness analysis, a method of economic evaluation, is used to describe how precision medicine can, in theory, exploit identifiable patient-level heterogeneity to improve population health outcomes and the relative cost-effectiveness of health care. Four case studies are used to illustrate potential challenges when demonstrating the economic case for a precision medicine in practice.

Expert commentary: The economic case for a precision medicine should be considered at an early stage during its research and development phase. Clinical and economic evidence can be generated iteratively and should be in alignment with the objectives and requirements of decision-makers. Programmes of further research, to demonstrate the economic case of a precision medicine, can be prioritized by the extent that they reduce the uncertainty expressed by decision-makers.

1. Introduction

Precision medicine, and related concepts including personalized and stratified medicine, is growing in prominence within the scientific literature and clinical practice [1]. Precision medicine is inclusive of, but not limited to, the targeting of health care interventions to patients that share a specific and identifiable set of characteristics [2]. Most applications to date have used a single test, as a companion diagnostic, to target a defined medicine to a known subgroup of patients. Applications of precision medicine may also include algorithm-based prescribing [3], risk-stratification within population screening programmes [4], and the use of genomic-based diagnostics for rare inherited conditions [5].

The advancement of precision medicine into clinical practice has been highlighted as an agenda for national and international health policy [6,7]. A principal barrier to this advancement is in addressing the requirements of the payer or reimbursement agency for health care [8,9]. The economic case for precision medicine within this context rests, ultimately, on demonstrating value to decision-makers responsible for allocating finite resources for health care. The comparison of relevant alternatives in terms of their costs and consequences, within an economic evaluation, is one method to generate evidence that can inform health care resource allocation decisions [10].

An extensive literature of published economic evaluations of health technologies for precision medicine is developing [11–19] and, in 2016, some 45 systematic reviews on this topic were identified [20]. The specific challenges in designing and conducting economic evaluations of precision medicine have also been described [21–27]. This Special Report aims to build on this literature and explain the economic case for precision medicine within a framework (cost-effectiveness analysis [CEA]) for the economic evaluation of health technologies used by decision-makers in England [28]. Section 2 describes the theory of the economic case within this framework. Definitions of key economic terms are provided in Table 1. Four case studies illustrative of precision medicine (see Table 2) are presented in Section 3 to highlight if, and how, evidence to support their economic case exists in practice. The report concludes by discussing the generation of evidence to demonstrate the economic case for precision medicine.

2. The economic case: in theory

The maximization of population health is viewed to be a fundamental objective of any health care system; decision-makers responsible for recommending health technologies are assumed to pursue health maximization, subject to a finite budget for the provision of health care [29]. Any resource allocation decision, therefore, has an opportunity cost, expressed in terms of health forgone, such that those same resources could have otherwise been used to provide an alternative health technology [30]. Population health is subsequently maximized by recommending health technologies if their expected health benefit exceeds their opportunity cost [31,32].
Table 1. Glossary of key terms.

| Term                        | Definition                                                                                                                                 |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Cost-effectiveness analysis | A method of economic evaluation that compares the expected incremental cost and health outcomes derived from relevant alternative health technologies [10]. |
| Cost-effectiveness plane    | A plot to illustrate the incremental outcomes derived from an intervention health technology versus a relevant comparator [43].           |
| Cost-effectiveness threshold| The additional cost that must be imposed on the budget for health care to displace one QALY [30].                                      |
| Decision-analytic model     | A series of mathematical relationships that represent the progression of a patient’s diagnosis or disease and the impact of a health technology on diagnosis and/or disease progression. Model-based cost-effectiveness analyses can synthesize all available evidence to inform resource allocation decision-making [51]. |
| Decision uncertainty        | The probability of recommending a health technology that is not cost-effective [35].                                                      |
| Heterogeneity               | The variation in expected costs and consequences that can be explained by patient-level characteristics [37].                              |
| Methodological uncertainty  | The uncertainty with respect to the appropriate methods of performing an economic evaluation [83].                                        |
| Microcosting                | Estimation of the specific resources and associated unit costs of a health technology [71].                                               |
| Opportunity cost            | The (health) benefits forgone due to a change in the allocation of health care resources [30].                                           |
| Parameter uncertainty       | The uncertainty in the true value of each input within a decision-analytic model [87].                                                   |
| Structural uncertainty      | The uncertainty with respect to the structure (care pathways, model type) of an economic evaluation [86].                               |
| Quality-adjusted life years | A generic measure of outcome that has reference points of one (for full health) and zero (for death) [33].                               |
| Reference case              | Pre-defined preferred criteria for performing an economic evaluation [84].                                                                 |
| Value of information        | A set of methods to quantify the value of further research to reduce decision uncertainty [89].                                           |

Table 2. Case studies of precision medicine.

| Companion diagnostic for activating mutations of epidermal growth factor receptor tyrosine kinase. | To inform the prescribing of gefitinib for patients with non-small cell lung cancer. | Improved clinical effectiveness. | • Limited evidence from test result to cost and health outcomes for all diagnostics. |
| Thiopurine S-methyltransferase mutation genotyping or enzyme phenotyping. | To inform the prescribing of azathioprine for patients with eligible autoimmune diseases. | Reduced adverse drug reactions. | • Clinicians may implement testing strategy imperfectly. |
| Assays to detect anti-drug antibodies and to measure drug levels. | To inform the prescribing of monoclonal antibody tumor necrosis factor-α inhibitors for patients with eligible autoimmune diseases. | Improved health outcomes and/or reduced health care resource use. | • Different permutations of multiple tests are possible; |
| Next generation sequencing gene panel test. | To inform the diagnosis of inherited retinal dystrophies. | Improved diagnostic accuracy and potentially reduced health care resource use. | • Position of tests in care pathway may be uncertain; |
|                                      |                                                        |                                                                           | • The cost of novel testing strategies may be unknown. |

CEA is a method of economic evaluation that compares the expected incremental (cost and health) outcomes derived from relevant alternative health technologies [10]. Health outcomes may be expressed using a generic measure, such as quality-adjusted life years (QALYs), to facilitate comparability between different diseases [33]. Judgments regarding the relative cost-effectiveness of a health technology can be made with reference to decision rules that comprise incremental costs, QALYs, and a cost-effectiveness threshold [34,35]. A health technology with a positive expected incremental net benefit versus its relevant comparator(s) is indicative of (average) population health maximization and relative cost-effectiveness [36] (see Table 3).

Heterogeneity in expected costs and QALYs is also likely to exist, conditional on patient-level characteristics, such that subgroups of patients within a population may derive incremental net benefits from the health technology that differ systematically from expected population-level outcomes [37–39]. Precision medicine involves using a mechanism to reveal between-patient heterogeneity that was unobserved previously, for example, using a diagnostic test to measure the quantity of a biomarker predictive of differential treatment response and, consequently, incremental cost and health outcomes [40]. The economic case for precision medicine, in theory, is contingent on whether the expected net benefit of treating patients according to their subgroup is greater than that obtained from a relevant alternative strategy [39,41,42]. The cost-effectiveness plane [43] in Figure 1 illustrates three scenarios of incremental outcomes that may characterize a precision medicine and also be consistent with a positive incremental net benefit.
3. The economic case: in practice

Four case studies illustrative of clinical applications of precision medicine (see Table 2) are now presented. These case studies were selected to highlight specific examples of the process and challenges of demonstrating their economic case in practice.

3.1. Case study 1: testing activating mutations of EGFR-TK and gefitinib

Gefitinib is a first-generation tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) tumors known to have activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK). In 2005, the Food and Drug Administration (FDA) restricted gefitinib from being used to treat all patients with NSCLC [44]. Subsequent trial evidence revealed heterogeneity in response to gefitinib that was unobserved previously, with respect to EGFR-TK mutation status [45]. The FDA and European Medicines Agency, consequently, granted marketing authorization for gefitinib in patients with NSCLC that had activating mutations of EGFR-TK [46]. The economic case for gefitinib is based on the premise of improved clinical effectiveness by stratifying the population of NSCLC patients by EGFR-TK mutation status.

In 2010, the National Institute for Health and Care Excellence (NICE) in England published a technology appraisal of gefitinib [47]. The technology appraisal recommended gefitinib as first-line treatment for locally advanced or metastatic NSCLC with activating mutations of EGFR-TK, based on the results of an economic evaluation that suggested this was a cost-effective use of health care resources [47]. The diagnostic test to identify mutation status, however, was not specified within the product license of gefitinib [48]. As a consequence, different diagnostic tests were used within the health care system to establish mutation status [49], with unknown implications for the relative cost-effectiveness of gefitinib.

In response, in 2013, NICE evaluated 10 different testing strategies to identify activating mutations of EGFR-TK as part of the Diagnostics Assessment Programme [48]. A subset of testing strategies (n = 5) was recommended for routine clinical practice according to evidence of relative cost-effectiveness [49,50]. The economic case for using these tests was a challenge to establish, in practice, because cost and health outcome data were not available for every strategy. A de novo decision-analytic model-based CEA [51–53], therefore, addressed deficiencies in the evidence base by (i) assimilating all available evidence and (ii) ‘linking’ test accuracy and long-term outcome data from different studies or by assuming that the tests had ‘equal prognostic value’ [48,54]. NICE recommended that future studies could address these evidence limitations by comparing different methods to test activating mutations of EGFR-TK directly and to link these findings to patient outcomes.
3.2. Case study 2: testing TPMT status and azathioprine

Azathioprine is an effective treatment for autoimmune conditions such as Crohn’s disease and rheumatoid arthritis; however, a subset of patients may experience dose-limiting adverse drug reactions (ADR) such as severe profound neutropenia [55]. Patients exhibit potentially identifiable heterogeneity in developing ADR to azathioprine according to thiopurine S-methyltransferase (TPMT) enzyme activity. Defined pretreatment genotyping (to identify mutations in the gene that codes for TPMT) or phenotyping (to measure the levels of active TPMT enzyme) can be used to identify patients at high-risk of severe neutropenia [55]. The economic case for testing TPMT is based on the premise that identifying such patients will improve population health outcomes by reducing the quantity of ADRs and the associated cost of managing these harms.

Several published model-based cost-effectiveness analyses concluded that TPMT testing, to inform azathioprine prescribing decisions, was a dominant intervention (see Figure 1) that produced more health benefit at a lower cost compared with not testing [56]. However, a subsequent pragmatic randomized controlled trial found that the relative cost-effectiveness, suggested by these model-based studies, may not be realized in routine clinical settings because clinicians, potentially, failed to adjust their prescribing behavior according to the diagnostic information regarding the genotype of each patient [57]. The testing protocol suggested that clinicians should prescribe a higher starting dose of azathioprine (for example, 2–3mg/kg/day) to patients at low-risk of ADR, and a reduced starting dose of azathioprine (for example, 25–30mg/day) to those patients at-risk of ADR. In the trial, however, patients at-risk of ADR (heterozygous for the TPMT gene) received the same dose as those patients at a lower-risk (wild-type) and, consequently, there was no difference in the rate of azathioprine discontinuation due to ADRs between the arms of the trial (p = 0.59) [57,58]. The expected outcomes from the study concluded that TPMT testing to inform azathioprine prescribing decisions, rather than being a dominant intervention, reduced both health care costs by £421.06 and health outcomes by 0.008 QALYs simultaneously [57].

The potential economic case for precision medicine is reliant on the amenability of clinicians to follow a protocol for testing [25,27,59]. Model-based economic evaluations may assume implicitly that diagnostic testing protocols are followed. However, evidence of how diagnostic information, obtained from a test result, is used by clinicians within their routine decision-making is not always clear [60]. For example, clinical decisions may be challenging if the cut point for a continuous test result is disputed or if multiple treatment strategies are possible following a particular test result. In practice, therefore, the imperfect implementation [61] of a testing strategy, through clinicians’ prescribing behavior, may contribute to overestimating the net health gain obtained from a precision medicine [20].

3.3. Case study 3: monitoring therapeutic drug levels and/or anti-drug antibodies of tumor necrosis factor-α inhibitors

Monoclonal antibodies that inhibit tumor necrosis factor-α (TNFi), such as adalimumab, are a class of biologic therapies used widely in the management of autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis [62]. All medicines require circulating levels of the active drug to remain within a known therapeutic range for treatment effectiveness and safety (and, consequently, cost-effectiveness) [63]. Patients may develop immunogenicity against monoclonal TNFi antibodies, by producing anti-drug antibodies, resulting in drug levels reducing below the minimum required by the therapeutic range to be effective [64,65].

Detecting the presence of anti-drug antibodies and/or measuring the level of TNFi in the serum are two potentially useful sources of heterogeneity in treatment response between patients [66]. The measurement of these biomarkers may be used to inform if, and how, a monoclonal TNFi antibody is prescribed most appropriately in patients with relevant autoimmune conditions [67]. The economic case of using one, or both, of these biomarkers is based on the premise that improved health outcomes and/or reduced health care resource use may be achieved by identifying whether treatment should continue and/or dose adjustment is required. In 2016, NICE conducted a model-based CEA of adalimumab and infliximab anti-drug antibody and drug level testing for patients with Crohn’s disease, as part of the Diagnostics Assessment Programme [68]. The assessment concluded that there was insufficient evidence to recommend testing in routine clinical practice, driven by uncertainties in the accuracy, timing, and (health and cost) outcomes derived from testing [68].

Establishing the economic case for measuring more than one biomarker is a challenge, in practice, because different permutations of tests are possible, at different points along a care pathway, resulting in different expected cost and health outcomes [22]. For example, the NICE assessment of TNFi anti-drug antibody and drug level testing evaluated concurrent testing (both biomarkers measured at the same time) and reflex testing (anti-drug antibodies only measured if drug levels were not detected) in patients that had maintained response, or lost response, to their TNFi [68]. Model conceptualization methods may, therefore, be appropriate to inform the relevant comparator strategies and structure of a model-based economic evaluation [69,70].

In addition, the cost of a new test or prescribing algorithm may be unknown if it is not already being used in routine practice. Therefore, microcosting studies, which take a ‘bottom-up’ approach by measuring and valuing all resources required to use a health technology, can help to estimate the cost of a new diagnostic test in routine clinical practice [71]. For example, one manufacturer of the anti-drug antibody and drug level tests charged approximately £35 per patient for both tests (2015 prices, UK); however, a microcosting study estimated the cost of these tests to approximate £152.52 per patient if all resources to perform testing in routine clinical practice (such as an additional appointment, the analysis of samples, and the time to make a treatment decision) were accounted for [71].

3.4. Case study 4: next generation sequencing panel for inherited eye disease

Massively parallel sequencing technologies have supported the development of a next generation sequencing (NGS)
gene panel test for the diagnosis of inherited retinal dystrophies (IRD) [72]. Historically, IRD were diagnosed by performing a single Sanger sequence test for each gene ‘known’ to cause vision loss. The single gene tests were subject to national variation in availability and service delivery [73] due, in part, to the cost, technical, and practical complexities of testing [74]. NGS gene panels are now being used to diagnose IRD in clinical practice. The ‘Gene Dossier’ submitted to the UK Genetic Testing Network estimated that the gene panel test would require a total incremental investment of £5,244 compared to conventional single gene testing. Downstream cost savings may also be possible due to fewer consultant appointments for sequential testing [75]. However, to date, the cost-effectiveness of using gene panels to diagnose IRD has not been investigated.

The use of gene panels facilitates substitution away from time-consuming single-gene testing and, in turn, may enable more individuals to be tested [74,75]. However, short-term capacity constraints within the health care system may impose a limit the number of tests that can be performed. Capacity constraints are, typically, not accounted for within model-based cost-effectiveness analyses [76]. Therefore, in practice, the total net health benefit derived from a precision medicine may be overestimated if the capacity to perform a testing strategy is restricted.

The anticipated benefit of the gene panel test, in the absence of treatments to prevent loss of vision, is the achievement of an accurate and timely diagnosis with information on prognosis and risk to family members [77]. Gene therapies are being developed for subtypes of IRD, which will require an accurate diagnosis for trial participation and eligibility for any subsequent licensed therapy [78]. The gene panel test will also reveal the mutation status of those patients with IRD that are ineligible for gene therapy. This diagnostic information may have value to patients themselves, for example, by improving their own capability to make informed life decisions [79]. In practice, however, if decision-makers were to account for such consequences as a ‘benefit’ (in addition to health gain) to inform population health care resource allocation decisions, the opportunity cost of those consequences must also be accounted for in terms of increasing this uncertainty. The probability of recommending a health technology that is not cost-effective can be expressed as decision uncertainty [82]. The uncertainty present within an economic evaluation has been characterized in the literature as methodological, structural, and parameter uncertainty [83].

Methodological uncertainty describes the uncertainty with respect to the methods of performing an economic evaluation; for example, whether resource allocation decisions ought to account for the non-health outcomes described in Case Study 4 [26]. In practice, methodological uncertainty is resolved by the normative value judgments of a decision-maker, which may be expressed within preferred criteria for performing an economic evaluation, known sometimes as a ‘reference case’ [10,84]. Structural uncertainty refers to uncertainty with respect to the structure of an economic evaluation; for example, how a de novo decision-analytic model represents the uncertain positioning of the anti-drug antibody and drug level tests (Case Study 3) within an existing care pathway. The choice of decision-analytic model (for example, a Markov model or discrete event simulation) that best addresses the decision problem may itself be uncertain [85]. Methods exist that enable the impact of structural uncertainty on estimates of relative cost-effectiveness to be estimated, such as model averaging and the parameterization of structural assumptions [86]. Parameter uncertainty refers to the uncertainty in the true value of each input of an economic evaluation; for example, the accuracy and clinical effectiveness of the strategies to test for activating mutations of EGFR may be uncertain (Case Study 1). A probabilistic analysis is, therefore, necessary to handle parameter uncertainty by characterizing input parameters as distributions and simulating expected outcomes over these distributions [87,88].

Additional research has the potential benefit of reducing decision uncertainty and ‘value of information’ methods can provide a quantitative estimate of whether such research has value in reducing uncertainty in the economic evidence base [89,90]. Further research has value, in the context of relative cost-effectiveness, if its expected cost is less than its expected benefit. The upper-bound on the cost of further research can be estimated as the expected value of perfect information (EVPI) [90]. The expected value of partial perfect information (EVPPI) can estimate the upper-bound on the cost of research for specific (sets of) input parameters, such as long-term health outcomes, QALYs, or resource utilization [90]. The expected net benefit of sampling (ENBS) may estimate the value of specific study designs, for example, to inform the sample size of a trial, by accounting for the cost of research itself [91]. The ability of these methods to inform the design of future research may facilitate iterative economic evaluation [92], such that a de novo decision-analytic model may be built during the early development phase of a health technology, and subsequently refined, repopulated, and re-analyzed as more evidence is generated over the life cycle of the health technology [93–95].

Programmes of scientific research, such as biomarker discovery, can support the application of precision medicine and public resources for research have been diverted toward such programmes internationally [96]. Value of information
methods can be used to ensure that the evidence generated to support precision medicine is aligned with demonstrating value to decision-makers responsible for the allocation of limited resources for health care [97]. National funding schemes exist, such as those provided by Genome Canada [98], that encourage the development of an economic case for targeted treatment strategies or new diagnostics. The earlier the economic case for a new precision medicine is considered by manufacturers of diagnostic and pharmaceutical health technologies, and by organizations that fund research, the more likely the subsequent evidence base will be generated to inform health care decision-makers that the example of precision medicine is consistent with their objectives, such as population health maximization, and should be recommended for use in routine clinical practice.

5. Expert commentary
Precision medicine has the potential to improve population health outcomes and the relative cost-effectiveness of health care. The economic case for precision medicine should consider both the cost and consequences of revealing patient-level heterogeneity in a target population. Consideration of cost alone is not sufficient to inform population resource allocation decision-making. The benefits forgone, due to changes in the allocation of resources, must also be quantified. Generating evidence to support the economic case of a precision medicine in practice, however, can be a challenge. Manufacturers, analysts, and funders of research may improve their research and development activities by considering the evidenced required by later-stage decision-makers at an earlier time period in the process of evidence generation.

The economic evaluation of precision medicine, and the generation of further evidence, should be an iterative process rather than a one-time stand-alone activity. Decision-analytic modeling and the prospective collection of data, therefore, both have an important role in estimating the impact of using a diagnostic test in clinical practice on patients’ long-term cost and health outcomes. Value of information analyses can be used to prioritize programmes of research, in the presence of competing deficiencies in the evidence base of a precision medicine, according to their potential to reduce decision uncertainty.

6. Five-year view
Precision medicine may evolve further in the future by increasing the utilization of prescribing algorithms that incorporate multiple biomarkers predictive of a specific outcome in clinical practice. Developments in the methods to estimate the accuracy, effectiveness, and cost of testing multiple biomarkers would, in turn, be valuable to estimate the opportunity cost of such algorithms more appropriately. The production and application of genomic-based diagnostics (for example, whole-genome sequencing and whole-exome sequencing) within routine clinical practice may also progress in the future. Substantial investment in capital (for example, laboratory facilities or an IT infrastructure) may be required, or the existing capacity to implement testing may be insufficient, which imposes constraints on the delivery of health care and an opportunity cost on population health. Developments in the methods to evaluate the economic case for precision medicine, in the context of such capacity constraints, would also likely be informative to decision-makers. Increasing claims on finite resources for health care may also result in decision-makers supporting activities to disinvest in certain health care expenditures, which may be informed by precision medicine strategies. Decision-makers should, therefore, consider exploring social value judgments with respect to resource allocation decisions for health care, informed by members of the public, to support such disinvestment activities.

Key issues
- The economic case for a health technology can be made by comparing its cost and (health) consequences with those derived from a relevant alternative, according to the explicit objectives of a decision-maker responsible for the allocation of health care resources.
- In theory, the economic case for precision medicine can improve the relative cost-effectiveness of care by exploiting patient-level heterogeneity in cost and health outcomes.
- In practice, deficiencies in the (clinical and economic) evidence base, and the plausibility of assumptions, may make the economic case for precision medicine a challenge to demonstrate.
- Early consideration of the requirements expressed by decision-makers can improve the likelihood that appropriate evidence is produced to inform resource allocation decision-making. The economic case for precision medicine can be developed iteratively and the generation of further (clinical and economic) evidence can be prioritized according to the extent to which it reduces the uncertainty expressed by decision-makers.

Funding
This paper was supported by Medical Research Council (MR/M01665X/1); Engineering and Physical Sciences Research Council; Lupus UK.

Declaration of interest
SP Gavan is supported by two grants awarded to The University of Manchester for MASTERPLANS, funded by the Medical Research Council [grant number MR/M01665X/1] and Lupus UK. AJ Thompson is funded by a grant awarded to The University of Manchester for the Manchester Molecular Pathology and Innovation Centre (MMPathIC) by the Medical Research Council and the Engineering and Physical Sciences Research Council. K Payne has a research programme supported by grants awarded from: The National Institute for Health Research, the Medical Research Council, the Engineering and Physical Sciences Research Council, Lupus UK, and The Swedish Foundation for Humanities and Social Sciences. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

References
Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●) to readers.
1. Pearson E. Personalized medicine in diabetes: the role of ‘Omics’ and biomarkers. Diabet Med. 2016;33(6):712–717.
2. Trusheim M, Berndt E, Douglas F. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6(4):287–293.
3. Redekop W, Mladic D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(5):54–59.

4. Pashayan N, Pharoah P. Population-based screening in the era of genomics. Per Med. 2012;9(4):451–455.

5. Boycott K, Vanstone M, Bulman D, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–691.

6. Kaplan W, Wirtz V, Mantel-Teeuwisse A, et al. Priority medicines for Europe and the world 2013 update. 1. Geneva: World Health Organization; 2013.

7. Collins F, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.

8. Rogowski W, Grosse S, Khoury M. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009;10(7):489–495.

9. Rogowski W, Hartz S, John J. Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res. 2008;8(194):1–12.

10. Drummond M, Sculpher M, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4. Oxford: Oxford University Press; 2015.

• A key textbook that describes the methods of economic evaluation.

11. Phillips K, van Bebber S. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5(8):1139–1149.

12. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics. 2008;26(7):569–587.

13. Beaulieu M, De Denuis S, Lachaine J. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010;11(11):1573–1590.

14. Vegter S, Jansen E, Postma M, et al. Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Dev Res. 2010;71(8):492–501.

15. Wong W, Carlson J, Thariani R, et al. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacogenomics. 2010;28(11):1001–1013.

16. Hatz M, Schremsker K, Rogowski W. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics. 2014;32(5):443–455.

17. BERM E, De LOOFF M, Wilfert B, et al. Economic evaluation of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. PLoS One. 2016;11(1):1–22.

18. Oosterhoff M, van der Maas M, Steuten L. A systematic review of health economic evaluations of diagnostic biomarkers. Appl Health Econ Health Policy. 2016;14(1):51–65.

19. Plumpton C, Roberts D, Pirmohamed M, et al. A systematic review of economic evaluations of pharmacogenetic testing for prevention of adverse drug reactions. Pharmacogenomics. 2016;34(8):771–793.

20. Payne K, Gavan S, Wright S, et al. Cost-effectiveness analyses of genetic and genomic diagnostic technologies. Nat Rev Genet. 2018; Forthcoming.

• Explains the role of decision-analytic model-based cost-effectiveness analysis for genetic and genomic diagnostic technologies.

21. Payne K, Eden M, Davison N, et al. Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions. Per Med. 2017;14(3):235–247.

22. Shababuruddin F, Fleeman N, Payne K. Economic evaluations of personalized medicine: existing challenges and current developments. Pharmacogenomics Pers Med. 2015;2015(8):115–128.

23. Rogowski W, Payne K, Schnell-Indest P, et al. Concepts of ‘personalisation’ in personalized medicine: implications for economic evaluation. Pharmacoeconomics. 2015;33(1):49–59.

24. Payne K, Annemans L. Reflections on market access for personalized medicine: recommendations for Europe. Value Health. 2013;16(5):S32–S38.

25. Annemans L, Redekop W, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health. 2013;16(5):S20–S26.

26. Payne K, Thompson A. Economics of pharmacogenomics: rethinking beyond QALYs? Curr Pharmgenomics Pers Med. 2013;11(3):187–195.

27. Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833–1847.

28. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence; 2013. (NICE Process and Methods; PMG9).

29. Culyer A. The rationing debate: maximising the health of the whole community. The case for. BMJ. 1997;314(7081):667–669.

30. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the national institute for health and care excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503.

31. Culyer A. Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use. Health Econ Policy Law. 2016;11(4):415–432.

32. McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744.

33. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ. 1996;5(4):279–296.

34. Claxton K, Sculpher M, Culyer A. Mark Versus Luke? Appropriate methods for the estimation of public health interventions. York: The University of York; 2007. (ICHE Research Paper; 31).

35. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341–364.

36. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(2):s68–s80.

37. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Vol. 1. Oxford: Oxford University Press; 2006.

38. Stevens W, Normand C. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. Soc Sci Med. 2004;58(2):315–320.

39. Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26(9):799–806.

40. Phelps C, Mushlin A. Focusing technology assessment using medical decision theory. Med Decis Making. 1988;8(4):279–289.

41. Coyle D, Buxton M, O’Brien B. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 2003;12(5):421–427.

42. Espinoza M, Manca A, Claxton K, et al. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Making. 2014;34(8):951–964.

• Outlines the value of heterogeneity framework for cost-effectiveness analysis.

43. Black W. The CE plane: a graphical representation of cost-effectiveness. Med Decis Making. 1990;10(3):212–214.

44. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2010;11(8):1343–1357.

45. Mok T, Wu Y, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.

46. Bogdanowicz B, Hoch M, Hartranft M. Flipped script for gefitinib: a reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic non-small cell lung cancer. J Oncol Pract. 2017;23(3):203–214.

47. National Institute for Health and Care Excellence. Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell
lung cancer. London: National Institute for Health and Care Excellence; 2010. (Technology Appraisal Guidance; TA192).

48. Byron S, Crabbe N, George E, et al. The health technology assessment of companion diagnostics: experience of NICE. Clin Cancer Res. 2014;20(6):1469-1476.

- Describes some of the challenges experienced by NICE when evaluating companion diagnostics.

49. National Institute for Health and Care Excellence. EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer. London: National Institute for Health and Care Excellence; 2013. (Diagnostics Guidance; DG9).

50. Garfield S, Polisena J, Spinner D, et al. Health technology assessment for molecular diagnostics: practices, challenges, and recommendations from the medical devices and diagnostics special interest group. Value Health. 2016;19(5):577–587.

51. Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics. 2000;17(5):445–459.

52. Sculpher M, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15(7):677–687.

53. Buxton M, Drummond M, van Hout B, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 1997;6(3):217–227.

54. Woodward M, Joore M, Whiting P, et al. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2014;18(32):1–166.

55. Lennard L. Implementation of TPMT Testing. Br J Clin Pharmacol. 2014;77(4):704–714.

56. Payne K, Newman W, Gurgwitz D, et al. TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources’? Per Med. 2009;6(1):103–112.

57. Thompson A, Newman W, Elliott R, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17(1):22–33.

58. Newman W, Payne K, Tricker K, et al. A pragmatic randomized controlled trial of triophurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics. 2011;12(6):815–826.

59. Garrison L, Austin M. Linking pharmacogenetics-based diagnostics and drugs for personalized medicine. Health Affairs. 2006;25(5):1281–1290.

60. Payne K, Fargher E, Roberts S, et al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences. Value Health. 2011;14(1):121–134.

61. Fenwick E, Claxton K, Sculpher M. The value of implementation and uncertainty within pharmaceutical funding decisions. Int J Syst Decis. 2010;20(2):212–32.

62. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364–371.

63. Trow D, Neef C, Thomson A, et al. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit. 2005;27(1):10–17.

64. Garcés S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013;73(1):1947–1955.

65. Kriekae C, Rispons T, Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol. 2012;24(3):306–311.

66. Jani M, Chinyo H, Warren R, et al. Clinical utility of random anti-tumour necrosis factor drug-level testing and measurement of anti-drug antibodies on the long-term treatment response in rheumatoid arthritis. Arthritis Rheum. 2015;67(8):2011–2019.

67. Vincent F, Morand E, Murphy K, et al. Antidrug antibodies (ADAbs) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178.

68. National Institute for Health and Care Excellence. Therapeutic monitoring of TNF-alpha inhibitors in crohn’s disease (LISA-TRACKER ELISA Kits, IDKMonitor ELISA Kits, and promonitor ELISA Kits). London: National Institute for Health and Care Excellence; 2016. (Diagnostics Guidance; DG22).

69. Roberts M, Russell L, Paltiel D, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health. 2012;15(6):804–811.

70. Tappenden P. Problem structuring for health economic model development. In: Culver A, editor. Encyclopedia of health economics. Vol. 3. 1 ed. Oxford: Elsevier; 2014. p. 168–179.

71. Jani M, Gavan S, Dixon W, et al. A microcosting study of immunogenicity and TNF drug level tests for therapeutic monitoring in clinical practice. Rheumatology. 2016;55(12):2131–2137.

72. Davies W, Downes S, Fu J, et al. Next-generation sequencing in health-care delivery: lessons from the functional analysis of r-hodopin. Genet Med. 2012;14(11):891–899.

73. Harrison M, Birch S, Eden M, et al. Variation in healthcare services for specialist genetic testing and implications for planning genetic services: the example of inherited retinal dystrophy in the english NHS. J Community Genet. 2015;6(2):157–165.

74. O’Sullivan J, Mullaney B, Bhaskar S, et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet. 2012;49(5):322–326.

75. UK Genetic Testing Network. Gene Dossier: retinal degeneration disorders 105 gene panel. London: UK Genetic Testing Network; 2012.

76. Salleh S, Thokala P, Brennan A, et al. Discrete event simulation-based resource modelling in health technology assessment. Pharmacoconomics. 2017;35(10):989–1006.

77. Combs R, Hall G, Payne K, et al. Understanding the expectations of patients with inherited retinal dystrophies. Br J Ophthalmol. 2013;97(8):1057–1061.

78. Samiy N. Gene therapy for retinal diseases. J Ophthalmic Vis Res. 2014(4)(5):506–509.

79. Payne K, McAllister M, Davies L. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22(3):258–271.

80. Sculpher M, Claxton K, Pearson S. Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health. 2017;20(2):234–239.

81. Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoconomics. 2008;26(9):781–798.

82. Griffin S, Claxton K, Palmer S, et al. Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ. 2011;20(2):212–224.

83. Stevenson M, Tappenden P, Squires H. Methods for handling uncertainty within pharmaceutical funding decisions. Int J Syst Sci. 2014;45(1):60–68.

84. Neumann P, Sanders G, Russell L, et al. Cost-effectiveness in health and medicine. Vol. 2. Oxford: Oxford University Press; 2017.

85. Brennan A, Chick S, Davies R. A taxonomy of model structures for economic evaluation for NICE technology assessment. Health Technol Assess. 2006;10(15):1295–1310.

86. Bojke L, Claxton K, Sculpher M, et al. Characterizing structural uncertainty in decision analytic models: a review and application of methods. Value Health. 2009;12(5):739–749.

87. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14(4):339–347.

88. Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoconomics. 2000;17(5):479–500.

89. Wilson E. A practical guide to value of information analysis. Pharmacoconomics. 2015;33(2):105–121.

- An introduction to value of information analysis in the context of population resource allocation decision-making for health care.

90. Claxton K, Ginnelly L, Sculpher M, et al. A pilot study on the use of decision theory and value of information analysis as part of the NHS technology assessment programme. Health Technol Assess. 2004;8(31):1–118.
91. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996;5(6):513–524.

92. Sculpher M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997;2(1):26–30.

93. Annemans L, Genesté B, Jolain B. Early modelling for assessing health and economic outcomes of drug therapy. Value Health. 2000;3(6):427–434.

94. Steuten L, Ramsey S. Improving early cycle economic evaluation of diagnostic technologies. Expert Rev Pharmacoecon Outcomes Res. 2014;14(4):491–498.

95. Buisman L, Rutten-Van Mölken M, Postmus D, et al. The early bird catches the worm: early cost-effectiveness analysis of new medical tests. Int J Technol Assess Health Care. 2016;32(1–2):46–53.

96. Pohlhaus J, Cook-Deegan R. Genomics research: world survey of public funding. BMC Genomics. 2008;9(472):1–18.

97. Claxton K, Sculpher M. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24(11):1055–1068.

98. Genome Canada. Genomics: discovery, impact, success - Genome Canada Strategic Plan 2012-2017. Ottawa, ON: Genome Canada; 2012.